FDA Adulteration and Misbranding Charges

Criminal Prosecution Under the Federal Food, Drug, and Cosmetic Act (FDCA)

Federal criminal prosecutions for FDA adulteration and misbranding charges have become one of the most aggressive—and least understood—frontiers of modern white-collar enforcement. Conduct that was once addressed through inspections, warning letters, or civil remedies is now increasingly charged as felony crime, placing physicians, clinic owners, manufacturers, and executives at risk of prosecution under the Federal Food, Drug, and Cosmetic Act (FDCA).

At Chapman, Dowling & Mallek, we represent healthcare professionals and regulated businesses nationwide in these high-stakes matters. This page explains how FDA adulteration and misbranding charges work, the statutes prosecutors rely upon, who investigates these cases, and why they raise profound concerns about overcriminalization, due process, and regulatory overreach.

 

What Is FDA “Adulteration”?

Under federal law, a drug, medical device, or healthcare product may be deemed “adulterated” if it allegedly fails to meet statutory or regulatory requirements—even where no patient has been harmed.

The primary statute governing adulteration is 21 U.S.C. § 351, which defines when drugs and devices are considered adulterated.

Under this provision, the government may claim a product is adulterated if it was allegedly:

• Manufactured, prepared, packed, or held outside FDA regulatory specifications
• Maintained in conditions regulators later characterize as “unsanitary”
• Non-compliant with FDA-defined quality system requirements
• Held “for sale” under conditions the government asserts do not meet regulatory standards

Critically, the statute does not require proof of patient injury, infection, or even exposure to actual risk. In criminal cases, this has allowed prosecutors to pursue charges based on hypothetical or purely regulatory theories rather than real-world harm.

 

What Is FDA “Misbranding”?

Misbranding is governed primarily by 21 U.S.C. § 352, which authorizes criminal liability where the government alleges that:

• Labeling is false or misleading in any respect
• Required information is missing or deemed inadequate
• Instructions for use are allegedly insufficient
• Warnings are retroactively judged inadequate by regulators

Like adulteration, misbranding prosecutions frequently turn on subjective regulatory interpretation—not fraud, intent to deceive, or patient harm.

 

The Criminal Enforcement Statute: 21 U.S.C. § 331

Most FDA criminal cases are charged under 21 U.S.C. § 331, the statute defining prohibited acts. It makes it a federal offense to:

• Introduce or deliver adulterated or misbranded products into interstate commerce
• Cause adulteration or misbranding
• Hold allegedly adulterated products “for sale”

Because healthcare providers, clinics, and manufacturers routinely operate in interstate commerce, this statute is exceptionally broad—granting prosecutors sweeping discretion.

 

Civil vs. Criminal Enforcement — Why This Shift Matters

Historically, FDA adulteration and misbranding issues were resolved through:

• Warning letters
• Inspections and corrective action plans
• Civil monetary penalties
• Product recalls
• Administrative proceedings

Criminal prosecution was reserved for intentional misconduct, repeat violations, or cases involving clear patient harm.

In recent years, however, the Food and Drug Administration and the Department of Justice have increasingly pursued criminal charges for regulatory disputes—even where:

• The practices were common across the industry
• Protocols aligned with Centers for Disease Control and Prevention guidance
• State medical boards approved the conduct
• No patient was injured

This enforcement shift has raised serious concerns about the criminalization of healthcare regulation.

 

Who Investigates FDA Adulteration and Misbranding Cases?

FDA criminal cases are typically investigated by the FDA Office of Criminal Investigations (OCI)—a federal law-enforcement agency with armed agents and arrest authority.

OCI works closely with:

• U.S. Attorney’s Offices
• DOJ Consumer Protection Branch
• FBI
• HHS-OIG
• CDC (in select cases)

These investigations often begin as routine inspections and escalate into criminal matters without clear notice to the target.

 

How These Investigations Commonly Begin

FDA adulteration and misbranding cases frequently originate from:

• Routine FDA inspections
• Employee complaints or whistleblowers
• Competitor reports
• Adverse-event submissions
• Billing audits that quietly expand into regulatory review

What appears to be a compliance issue can evolve—often silently—into a criminal investigation.

 

Common Defense Issues in FDA Criminal Cases

Many FDA adulteration prosecutions share recurring legal and factual weaknesses.

1. No Patient Harm

In numerous cases, the government cannot establish that:

• Any patient was injured
• Any device was actually used
  
• Any infection or adverse outcome occurred

Yet prosecutions proceed regardless.

2. Subjective Expert Standards

Cases often rely on:

• A single government expert’s opinion
• Standards absent from statutes or peer-reviewed literature
• After-the-fact interpretations rather than published guidance

This creates significant due-process concerns.

3. Conflict with CDC or Medical Board Guidance

Defense teams frequently uncover that:

• CDC-approved protocols were followed
• State medical boards inspected and approved the practices
• Widely accepted industry conduct was retroactively labeled “criminal”

These conflicts are fertile ground for dismissal and appellate challenges.

4. Evidence Preservation and Disclosure Violations

FDA prosecutions commonly raise issues involving:

• Brady v. Maryland violations
• Giglio impeachment failures
• Jencks Act violations (18 U.S.C. § 3500)
• Failure to preserve or disclose investigator communications

Discovery violations can fundamentally undermine the prosecution.

 

Why These Charges Are Especially Dangerous

FDA adulteration and misbranding statutes operate as strict-liability offenses in many contexts. That means:

• Criminal intent may not be required
• Good-faith compliance efforts may not protect you
• Hypothetical risk can substitute for actual harm

For physicians, clinics, hospitals, and manufacturers, this creates extraordinary criminal exposure for regulatory disagreements.

 

When to Contact an FDA Criminal Defense Lawyer

You should seek experienced counsel immediately if:

• FDA OCI agents contact you
• Your facility is subject to repeated inspections
• Devices or records are seized
• You receive a subpoena or target letter
• Regulatory matters begin shifting toward criminal allegations

Early intervention is often the difference between administrative resolution and felony prosecution. Chapman, Dowling & Mallek routinely steps in at this critical stage to protect clients before charges are filed.

 

Final Thought

FDA adulteration and misbranding laws were enacted to protect public health—not to criminalize good-faith medical judgment, CDC-approved protocols, or industry-standard practices in the absence of harm.

As recent prosecutions make clear, regulatory discretion has increasingly given way to criminal enforcement. For anyone operating in FDA-regulated spaces, experienced white-collar defense counsel is no longer optional—it is essential.

 

FDA Charges Guides

• FDA Authority vs. Medical Practice
• FDA Criminal Defense FAQ
• Defending FDA Criminal Cases
• The DOJ-FDA Strike Force
• FDA Adulteration and Misbranding Charges